ALBTHIGH SIGNALRISK10-K

ALBT has undergone a complete business transformation from a diagnostic/laboratory services company to an AI-focused technology company while experiencing severe cash depletion and massive losses.

The company has fundamentally pivoted its entire business model, abandoning its previous focus on breathalyzer devices and laboratory services to pursue AI acquisitions and technology markets. This represents a complete strategic overhaul that introduces significant execution risk and uncertainty about management's ability to successfully operate in an entirely different industry vertical.

Comparing 2026-03-30 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

ALBT's financial condition has deteriorated dramatically, with cash plummeting 96% to just $109K while net losses more than doubled to $18.3M and interest expenses surged 422%. Despite the severe cash burn and widening losses, stockholders' equity paradoxically increased 30%, likely due to equity raises that have since been spent down. The company appears to be in a critical cash position while pursuing an expensive business transformation, creating substantial near-term liquidity risk.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+1167%
$2K$22K

Capital expenditure jumped 1167% — major investment cycle underway; assess returns on deployment.

Interest Expense
P&L
+422%
$34K$176K

Interest expense surged 422% — significant debt increase or rising rates materially impacting earnings.

Inventory
Balance Sheet
+387.2%
$3K$13K

Inventory surged 387.2% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Net Income
P&L
-131.1%
-$7.9M-$18.3M

Net income declined 131.1% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
-96.2%
$2.9M$109K

Cash declined 96.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

R&D Expense
P&L
-85%
$731K$110K

R&D spending cut 85% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
-54.1%
-$4.9M-$7.6M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Current Assets
Balance Sheet
-53.8%
$3.2M$1.5M

Current assets declined 53.8% — monitor working capital adequacy and short-term liquidity.

Gross Profit
P&L
-34.2%
$415K$273K

Gross margin compression — rising input costs, pricing pressure, or unfavorable product mix shift.

Stockholders Equity
Balance Sheet
+30%
$7.1M$9.2M

Equity base grew 30% — retained earnings accumulation or equity issuance strengthening the balance sheet.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-31
ADDED
(Exact name of registrant as specified in its charter) Delaware 47-1685128 (State or other jurisdiction of (I.R.S.
The registrant intends to file its proxy statement within 120 days after its fiscal year end.
BUSINESS Overview We are a technology-innovation company with a strategic focus on developing innovative products and services that serve growing consumer health and technology markets.
Throughout our operating history, we have maintained our corporate identity, management team and original mission while strategically evolving our business in response to market conditions and commercial opportunities, with each such evolution being the product of deliberate decisions.
We are actively seeking complementary bolt-on AI acquisitions that could generate near-term revenue to supplement our current operations as both segments continue to develop.
+7 more — sign up free →
REMOVED
On October 28, 2024, the Company effectuated a reverse stock split of the Company s common stock at a ratio of 1-for-15 (the Reverse Stock Split ).
All amounts and values presented in this Annual Report on Form 10-K have been retroactively adjusted to reflect the Reverse Stock Split for all periods presented, unless otherwise indicated.
BUSINESS We are a commercial-stage company dedicated to developing and delivering precision diagnostic consumer products.
We are currently marketing the Keto Air breathalyzer device and plan to develop additional diagnostic uses of the breathalyzer technology.
We also provided laboratory services in 2024 and 2023, offering a broad portfolio of diagnostic tests, including drug testing, toxicology, and a broad array of test services, from general bloodwork to anatomic pathology, and urine toxicology.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →